


PERSONAL INFORMATION

Filippo Lodi

 Via Fosse Ardeatine 20, 40062 Molinella Bologna (Italy)

 (+39) 3395332642  (+39) 051 2143240

 filippo.lodi@aosp.bo.it
filippo.lodi3@unibo.it

Date of birth 13/10/1977 | Nationality Italian

WORK EXPERIENCE

2013–Present

Nuclear Medicine dept., PET Radiopharmacy, St.Orsola-Malpighi University Hospital, Bologna (Italy)

PET Radiopharmacist, Head of Production

PET radiopharmaceuticals for clinical application:

- Synthesis and quality control of PET radiopharmaceuticals labelled with F-18 and C-11: ^{18}F -FDG, ^{18}F -FLT, ^{18}F -NaF, ^{18}F -FACBC, ^{18}F -FDOPA ^{11}C -Choline, ^{11}C -Methionine, ^{11}C -Acetate, ^{11}C -MHED.
- Synthesis and quality control of PET radiopharmaceuticals labelled with Ga-68: ^{68}Ga -DOTANOC, ^{68}Ga -Citrate, ^{68}Ga -PSMA-11, ^{68}Ga -FAPI-46.
- Synthesis and quality control of PET radiopharmaceuticals labelled with Cu-64: ^{64}Cu -ATSM.
- Research on PET receptorial radiopharmaceuticals labelled with F-18 and C-11.
- Research on PET radiometals Ga-68, Cu-64 and I-124.

2010–2012

Nuclear Medicine dept., PET Radiopharmacy, St.Orsola-Malpighi University Hospital, Bologna (Italy)

Head of Quality Control

2008–2010

Nuclear Medicine dept., PET Radiopharmacy, St.Orsola-Malpighi University Hospital, Bologna (Italy)

Hospital pharmacist manager, PET Radiopharmacist

Production and quality control of PET radiopharmaceuticals for clinical and pre-clinical use

2004–2008

Nuclear Medicine dept., PET Radiopharmacy, St.Orsola-Malpighi University Hospital, Bologna (Italy)

Contract PET Radiopharmacist

Production and quality control of PET radiopharmaceuticals for clinical and pre-clinical use

2006–2008

European Institute of Oncology (IEO), Nuclear Medicine dept., Milan (Italy)

Contract Radiopharmacist

Synthesis and quality control of radiopharmaceuticals labeled with Y-90 and Lu-177 for receptorial targeting radiotherapy in tumours

EDUCATION AND TRAINING

2002 **Degree in Pharmaceutical Chemistry, Faculty of Pharmacy, University of Bologna**

Faculty of Pharmacy, University of Bologna, Bologna (Italy)

2003–2004 **Research grant**

Nuclear Medicine dept., PET Radiopharmacy, St.Orsola-Malpighi University Hospital, Bologna (Italy)

Synthesis and development of PET radiopharmaceuticals

2004 **Residential course for radiochemists: synthesis and quality control of PET Radiopharmaceuticals**

Scientific Institute Hospital S. Raffaele, Milan (Italy)

2005 **Graduated school in Hospital Pharmacy**

Faculty of Pharmacy, University of Bologna, Bologna (Italy)

2006 **Scientific collaboration: PET radiopharmaceuticals labelling**

Hebrew University Medical School, Jerusalem (Israel)

Scientific collaboration with Hadassah Hospital Cyclotron Radiochemistry Unit: synthesis and quality control of PET receptorial tracers labelled with C-11, F-18 and I-124 targeting EGFR.

PERSONAL SKILLS

Mother tongue(s) Italian

Foreign language(s)

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	B2	B2	B2	B2	B2

Levels: A1 and A2: Basic user - B1 and B2: Independent user - C1 and C2: Proficient user
Common European Framework of Reference for Languages

Organisational / managerial skills PET Radiopharmacy head (currently responsible for a team of 10 people)

Job-related skills

Good teamwork skills

Good knowledge and experience on:

technologies for automated synthesis and dispensing of PET radiopharmaceuticals labelled with F-18, C-11 and Ga-68: synthesis modules, dispensing and sterilization devices, hot cells and isolators.

Analytical techniques for quality control of PET radiopharmaceuticals: chromatographic techniques: HPLC, GC-FID, TLC.

Production of radionuclides with medical cyclotron

Production of radionuclides with generator

Tutor for International Atomic Energy Agency (IAEA) fellowship programmes

Reviewer for national and international conferences

Reviewer of journals in the field of nuclear medicine and radiopharmacy

Author and co-author of abstracts presented at nuclear medicine and radiopharmaceutical chemistry conferences

Digital skills

SELF-ASSESSMENT				
Information processing	Communication	Content creation	Safety	Problem-solving
Independent user	Independent user	Independent user	Independent user	Basic user

Digital skills - Self-assessment grid

ADDITIONAL INFORMATION

Memberships

European Association of Nuclear Medicine (EANM) Radiopharmacy Committee: member

European Association of Nuclear Medicine (EANM): member

Italian Group of Radiopharmaceutical Chemistry (GICR): member

Italian Group of Radiopharmaceutical Chemistry (GICR): 2012-2016 member of the Board (treasurer)

Teaching experience

2019-2020: contract professor, Graduated School of Hospital Pharmacy, radiopharmacy course, University of Bologna

2018: Azienda Ospedaliero-Universitaria di Bologna Policlinico St.Orsola-Malpighi: Brazilian Nuclear Medicine Society (SBMN) Residential course on nuclear medicine in prostate

2017: Azienda Ospedaliero-Universitaria di Bologna Policlinico St.Orsola-Malpighi: Brazilian Nuclear Medicine Society (SBMN) Residential course on nuclear medicine in prostate

2013-2014: contract professor, Nuclear Medicine Technologist radiopharmaceuticals course, University of Bologna

2010: Azienda Ospedaliero-Universitaria di Bologna Policlinico St.Orsola-Malpighi: Residential Course of the Italian Association of Nuclear Medicine (AIMN)

2007: Azienda Ospedaliero-Universitaria di Bologna Policlinico St.Orsola-Malpighi: Residential Course of the Italian Association of Nuclear Medicine (AIMN)

2006: Azienda Ospedaliero-Universitaria di Bologna Policlinico St.Orsola-Malpighi: Residential Course of the Italian Association of Nuclear Medicine (AIMN)

Presentations

INVITED TALKS AT NATIONAL AND INTERNATIONAL MEETINGS

2020: VIII Congresso Nazionale del Gruppo Interdisciplinare di Chimica dei Radiofarmaci (GICR). Padova 18-19 Settembre 2020. ⁶⁸Ga/¹⁸F-FAPI: *Premesse e Promesse*.

2019: 9° Corso teorico-pratico Nazionale del Gruppo Interdisciplinare di Chimica dei Radiofarmaci (GICR). Sperimentazione con radiofarmaci: Radiometalli dalla chimica alle applicazioni nella

diagnostica medico-nucleare. Novembre 2019. *“Dalla radiochimica ai kit per marcatura di radioisotopi metallici”*.

2019: La Documentazione e l'utilizzo dei sistemi informatici in Radiofarmacia. Corso di aggiornamento della Società Italiana di Farmacia Ospedaliera (SIFO). Torino 4 Ottobre 2019 *“I Sistemi Informatici per Medicina Nucleare e la Gestione del Dato Strumentale”*.

2017: 7° Corso Nazionale di Aggiornamento del Gruppo Interdisciplinare di Chimica dei Radiofarmaci (GICR). Sperimentazione con radiofarmaci: aspetti normativi ed esperienze pratiche. 18 novembre 2017. *“La scrittura di un IMPD per diagnostica [⁶⁸Ga]Ga-PSMA. Punti critici e consigli pratici”*.

2017: Problematiche inerenti al controllo di qualità e alla gestione della camera calda – Corso avanzato. Pavia, 20 maggio 2017. *“⁶⁸Ga: il Controllo di Qualità dal Generatore al Radiofarmaco”*.

2017: 13° Congresso nazionale dell'Associazione Italiana di Medicina Nucleare ed Imaging Molecolare (AIMN), Rimini. *“Radiofarmaci in Farmacopea”*

2017: 13° Congresso nazionale dell'Associazione Italiana di Medicina Nucleare ed Imaging Molecolare (AIMN), Rimini. *“Generatori di Radionuclidi PET”*

2017: Radiopharmacy seminar, German Cancer Research Center (DFKZ) Heidelberg, Germany. *“Impact of ¹¹C-chemistry on Clinical Radiopharmacy”*

2016: 12th Radiopharmacy and cyclotron User forum G.E. Healthcare, Barcellona, Spain. *“PET Tracers for Prostate Cancer Imaging: Perspectives from Clinical Radiopharmacy”*.

2016: Istituto Clinico Scientifico Maugeri. Problematiche inerenti al controllo di qualità e alla gestione della camera calda – Corso avanzato. Pavia, 20 maggio 2016. *“Sintesi e controllo di qualità dei radiofarmaci PET”*.

2015: 4° Corso Nazionale di Aggiornamento del Gruppo Interdisciplinare di Chimica dei Radiofarmaci (GICR) Il Controllo di Qualità dei Radiofarmaci: Strumenti, Materiali e Metodi, Milano, 28 novembre 2015. *“Radiofarmaci PET ottenuti da generatore [⁶⁸Ga]DOTA-peptidi”*.

2015: Annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2015, Baltimora, USA. *“PET Radiopharmaceuticals in oncology beyond 18F-FDG”*.

2013: 9th Radiopharmacy and cyclotron User forum G.E. Healthcare, Lyon, France. *“¹⁸F-FACBC production on FASTLab in clinical PET Radiopharmacy”*.

2012: 95th Canadian Chemistry Conference and Exhibition, Radiopharmaceutical Symposium, Calgary, Canada. *“⁶⁸Ga: a generator produced radionuclide for Positron Emission Tomography”*.

2011: Azienda Ospedaliero-Universitaria di Bologna Policlinico S.Orsola-Malpighi: Convegno *“Produzione di Radionuclidi per Impieghi Clinici”*: *“Norme di Buona Preparazione (NBP)”*

2009: III Congresso nazionale GICR (Gruppo Interdisciplinare di Chimica dei Radiofarmaci), Pavia. *“Sistemi automatizzati per radiofarmaci PET ¹¹C”*.

2007: Azienda Unità Sanitaria Locale di Bologna, Ospedale Maggiore, Bologna. Corso: *“La preparazione dei radiofarmaci presso le strutture di Medicina Nucleare: aspetti tecnici, normativi ed organizzativi ad un anno dalla entrata in vigore delle norme previste dalla XI Farmacopea Italiana. “Radiofarmaci PET marcati con ¹¹C: impiego clinico e prospettive future”*.

2003: Azienda Ospedaliero-Universitaria di Bologna Policlinico S.Orsola-Malpighi:

Meeting scientifici. "Nuove applicazioni dei ^{11}C -Traccianti".

Publications **EDITED PAPERS ON SCIENTIFIC JOURNALS**

Calderoni L, Farolfi A, Pianori D, Maietti E, Cabitza V, Lambertini A, Ricci G, Telo S, **Lodi F**, Castellucci P, Fanti S. Evaluation of an Automated Module Synthesis and a Sterile Cold Kit-Based Preparation of ^{68}Ga -PSMA-11 in Patients with Prostate Cancer. *J Nucl Med*. 2020 May;61(5):716-722.

Lucia Zanoni, Alessandro Broccoli, Alessandro Lambertini, Cinzia Pellegrini, Vittorio Stefoni, **Filippo Lodi**, Cristina Fonti, Cristina Nanni, Pier Luigi Zinzani, Stefano Fanti. Role of ^{18}F -FLT PET/CT in suspected recurrent or residual lymphoma: final results of a pilot prospective trial. *Eur J Nucl Med Mol Imaging* 2019 Jul;46(8):1661-1671.

Calderoni L, Matei Deliu V, Farolfi A, Lambertini A, Renne G, Lorenzini D, Cervati V, **Lodi F**, Castellucci P, Fanti S. Single Subcutaneous Prostate Cancer Metastasis Detected by ^{68}Ga -PSMA PET/CT During Early Biochemical Relapse: A Case Report. *Clin Genitourin Cancer*. 2019 Apr;17(2):e356-e359.

Riga S, Cicoria G, Pancaldi D, Zagni F, Vichi S, Dassenno M, Mora L, **Lodi F**, Morigi MP, Marengo M. Production of Ga-68 with a General Electric PETtrace cyclotron by liquid target. *Phys Med*. 2018 Nov;55:116-126.

Ceci F, Castellucci P, Graziani T, Farolfi A, Fonti C, **Lodi F**, Fanti S. ^{68}Ga -PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy. *Eur J Nucl Med Mol Imaging*. 2019 Jan;46(1):31-39.

Farolfi A, Ceci F, Castellucci P, Graziani T, Siepe G, Lambertini A, Schiavina R, **Lodi F**, Morganti AG, Fanti S. ^{68}Ga -PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml. Efficacy and impact on treatment strategy. *Eur J Nucl Med Mol Imaging*. 2019 Jan;46(1):11-19.

A. Matti, G. M. Lima, L. Zanoni, C. Pultrone, R. Schiavina, **F. Lodi**, S. Fanti and C. Nanni. Interpretation of ^{11}C -choline PET/CT for the diagnosis of local relapse in radically treated prostate cancer. *European Journal of Hybrid Imaging* (2017) 1:5.

Lopci E, Grizzi F, Russo C, Toschi L, Grassi I, Cicoria G, **Lodi F**, Mattioli S, Fanti S. Early and delayed evaluation of solid tumours with ^{64}Cu -ATSM PET/CT: a pilot study on semiquantitative and computer-aided fractal geometry analysis. *Nucl Med Commun*. 2017 Apr;38(4):340-346

Boschi S, Lee JT, Beykan S, Slavik R, Wei L, Spick C, Eberlein U, Buck AK, **Lodi F**, Cicoria G, Czernin J, Lassmann M, Fanti S, Herrmann K. Synthesis and preclinical evaluation of an Al ^{18}F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand. *Eur J Nucl Med Mol Imaging*. 2016 Nov;43(12):2122-2130

Graziani T, Ceci F, Castellucci P, Polverari G, Lima GM, **Lodi F**, Morganti AG, Ardizzoni A, Schiavina R, Fanti S. (11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series. *Eur J Nucl Med Mol Imaging*. 2016 Oct;43(11):1971-9.

Vichi, Sara; Infantino, Angelo; Cicoria, Gianfranco; Pancaldi, Davide; Mostacci, Domiziano; **Lodi, Filippo**; Marengo, Mario. An innovative gamma-ray spectrometry system using a compact and portable CZT detector for radionuclidic purity tests of PET radiopharmaceuticals. *Radiation effects and defects in solids*. 2016, 171, pp. 726 - 735

Gagliardi C, Tabacchi E, Bonfiglioli R, Diodato S, Nanni C, Guidalotti P, Lorenzini M, Lodi F, Milandri A, Rapezzi C, Fanti S. Does the etiology of cardiac amyloidosis determine the myocardial uptake of [18F]-NaF PET/CT? *J Nucl Cardiol*. 2017 Apr;24(2):746-749

Nanni C, Zanoni L, Pultrone C, Schiavina R, Brunocilla E, **Lodi F**, Malizia C, Ferrari M, Rigatti P, Fonti C, Martorana G, Fanti S. (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial. *Eur J Nucl Med Mol Imaging*. 2016 Aug;43(9):1601-10.

Lopci E, Grassi I, Rubello D, Colletti PM, Cambioli S, Gamboni A, Salvi F, Cicoria G, **Lodi F**, Dazzi C, Mattioli S, Fanti S. Prognostic Evaluation of Disease Outcome in Solid Tumors Investigated With ⁶⁴Cu-ATSM PET/CT. *Clin Nucl Med*. 2016 Feb;41(2): 87-92.

Boschi S, **Lodi F**, Boschi L, Nanni C, Chondrogiannis S, Colletti PM, Rubello D, Fanti S. ¹¹C-Meta-Hydroxyephedrine: A Promising PET Radiopharmaceutical for Imaging the Sympathetic Nervous System. *Clin Nucl Med*. 2015 Feb;40(2):96-103.

Zagni F, Cicoria G, Lucconi G, Infantino A, **Lodi F**, Marengo M. Monte Carlo modeling provides accurate calibration factors for radionuclide activity meters. *Appl Radiat Isot*. 2014 Dec;94:158-65.

Lopci E, Grassi I, Chiti A, Nanni C, Cicoria G, Toschi L, Fonti C, **Lodi F**, Mattioli S, Fanti S. PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence. *Am J Nucl Med Mol Imaging*. 2014 Jun 7;4(4):365-84.

Castellucci P, Ceci F, Graziani T, Schiavina R, Brunocilla E, Mazzarotto R, Pettinato C, Celli M, **Lodi F**, Fanti S. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging ¹¹C-Choline PET/CT scan before salvage radiation therapy? *J Nucl Med*. 2014 Sep;55(9):1424-9.

Ceci F, Castellucci P, Graziani T, Schiavina R, Brunocilla E, Mazzarotto R, Ntreta M, **Lodi F**, Martorana G, Fanti S. ¹¹C-choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT. *Eur J Nucl Med Mol Imaging*. 2014;41(5):878-86.

C. Quarta, **F. Lodi**, R. Mazza, F.A. Giannone, L. Boschi, C. Nanni, E. Nisoli, S. Boschi, R. Pasquali, S. Fanti, P. Iozzo, U. Pagotto. ¹¹C-meta-hydroxyephedrine PET/CT imaging allows in vivo study of adaptive thermogenesis and white-to-brown fat conversion. *Molecular Metabolism, Mol Metab*. 2013;2(3):153-60.

Lucconi G, Cicoria G, Pancaldi D, **Lodi F**, Malizia C, Fanti S, Boschi S, Marengo M. Use of ⁶⁵Zn as a tracer for the assessment of purification in the ⁶⁸Ga-DOTANOC synthesis. *Appl Radiat Isot*. 2013 May 30;80C:27-31.

Belosi F, Cicoria G, **Lodi F**, Malizia C, Fanti S, Boschi S, Marengo M. Generator Breakthrough and Radionuclidic Purification in Automated Synthesis of ⁶⁸Ga-DOTANOC. *Curr Radiopharm*. 2013 Jun 6;6(2):72-7.

S.Boschi, **F.Lodi**, C.Malizia, G.Cicoria and M.Marengo. Automation synthesis modules review. *Appl Radiat Isot*. 2013 Jun;76:38-45

Quarta C, Cantelli E, Nanni C, Ambrosini V, D'ambrosio D, Di Leo K, Angelucci S, Zagni F, **Lodi F**, Marengo M, Weiss WA, Pession A, Tonelli R, Fanti S. Molecular Imaging of Neuroblastoma Progression in TH-MYCN Transgenic Mice. *Mol Imaging Biol*. 2013 15(2):194-202.

Lodi F, Malizia C, Castellucci P, Cicoria G, Fanti S, Boschi S. Synthesis of oncological [¹¹C]radiopharmaceuticals for clinical PET. *Nucl Med Biol*. 2012; 39(4): 447-60.

Paolo Castellucci, Javier Pou Ucha, Chiara Fuccio, Domenico Rubello, Valentina Ambrosini, Gian Carlo Montini, Vincenzina Pettinato, Claudio Malizia, **Filippo Lodi**, and Stefano Fanti. Incidence of Increased ⁶⁸Ga-DOTANOC Uptake in the Pancreatic Head in a Large Series of Extraprostatic NET Patients Studied with Sequential PET/CT. *Journal of Nuclear Medicine* 2011;52 (6): 886-90.

Pantaleo MA, Mishani E, Nanni C, Landuzzi L, Boschi S, Nicoletti G, Dissoki S, Paterini P, Piccaluga PP, **Lodi F**, Lollini PL, Fanti S, Biasco G. Evaluation of modified PEG-anilinoquinazoline derivatives as potential agents for EGFR imaging in cancer by small animal PET. *Mol Imaging Biol.* 2010 Dec;12(6):616-25.

Alessandra Maleddu, Maria A Pantaleo, Paolo Castellucci, Maria Astorino Cristina Nanni, Margherita Nannini, Fiorenza Busato, Monica Di Battista, Mohsen Farsad, **Filippo Lodi**, Stefano Boschi, Stefano Fanti, and Guido Biasco. ^{11}C -acetate PET for early prediction of sunitinib response in metastatic renal cell carcinoma. *Tumori*, 2009;95, 382-384.

Stefano Boschi, **Filippo Lodi**, Gianfranco Cicoria, Jorge Raoul Ledesma, Anna Rizzello, Donato Di Pierro, Silvia Trespidi, Roger Knopp, Mario Marengo. Development of a modular system for PET [^{11}C]labelled radiopharmaceuticals. *Appl Radiat Isot.* 2009 ;67(10):1869-73.

Paolo Castellucci , Chiara Fuccio, Cristina Nanni, Ivan Santi, Anna Rizzello, **Filippo Lodi**, Riccardo Schiavina, Alessandro Franceschelli, Giuseppe Martorana, Fabio Manfredi, Stefano Fanti. Influence of trigger PSA and PSA kinetics on ^{11}C -Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. *J Nucl Med.* 2009 Oct;50(10):1578.

Pantaleo MA, Landuzzi L, Nicoletti G, Nanni C, Boschi S, Piazza G, Santini D, Di Battista M , Castellucci P, **Lodi F**, Fanti S , Lollini P-L, Biasco G. Advances in preclinical therapeutics development using small animal imaging and molecular analyses: the Gastrointestinal Stromal Tumors (GISTs) model. *Clin Exp Med.* 2009 Sep;9(3):199-205.

A. Rizzello, D. Di Pierro , **F. Lodi**, S. Trespidi, G. Cicoria, D. Pancaldi, C. Nanni, M. Marengo and S. Boschi. Synthesis and Quality Control of the ^{68}Ga -citrate in Routine Clinical PET. *Nucl Med Commun.* 2009 Jul;30(7):542-5.

Gianfranco Cicoria, Mario Marengo, Davide Pancaldi, Donato Di Pierro, Anna Rizzello, **Filippo Lodi**, Stefano Fanti, Stefano Boschi. Acceptance tests and quality control of $^{68}\text{Ge}/^{68}\text{Ga}$ generators. *Current Radiopharmaceuticals* 2009, 2: 165-168.

Pantaleo MA, Nannini M, Maleddu A, Fanti S, Nanni C, Boschi S, **Lodi F**, Nicoletti G, Landuzzi L, Lollini PL, Biasco G. Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFR) in cancer. *Ann Oncol.* 2009; 20 (2): 213-26.

Nanni C, Rubello D, Zamagni E, Castellucci P, Ambrosini V, Montini G, Cavo M, **Lodi F**, Pettinato C, Grassetto G, Franchi R, Gross MD, Fanti S. ^{18}F -FDG PET/CT in myeloma with presumed solitary plasmocytoma of bone. *In Vivo.* Jul-Aug;22(4) 2008, 513-7.

M.A. Pantaleo, M. Nannini, E. Lopci, P. Castellucci, A. Maleddu, **F. Lodi**, C. Nanni, V. Allegri, M. Astorino, G. Brandi, M. Di Battista, S. Boschi, S. Fanti and G. Biasco. Molecular imaging and targeted therapies in oncology: New concepts in treatment response assessment. A collection of cases. *Int J Oncol.* 2008 Sep;33(3):443-52.

Filippo Lodi, Anna Rizzello, Silvia Trespidi, Donato di Pierro, Mario Marengo, Mohsen Farsad, Stefano Fanti, Domenico Rubello and Stefano Boschi. Reliability and reproducibility of N- ^{11}C]-methylcholine and L-(S-methyl- ^{11}C)]methionine solid-phase synthesis: a useful and suitable method in clinical practice. *Nuc. Med. Comm.* Aug; 29(8) (2008), 736-40.

Giulia Magini, Mohsen Farsad, Marta Frigerio, Carla Serra, AntonioColecchia, Elio Jovine, Marco Vivarelli, Valentina Feletti, Rita Golfieri, Corrado Patti, Stefano Fanti, Roberto Franchi, **Filippo Lodi**, Stefano Boschi, Mauro Bernardi, Franco Trevisani. C-11 Acetate does not enhance usefulness of F-18 FDG PET/CT in differentiating between focal nodular hyperplasia and hepatic adenoma. *Clinical Nuclear*, 34, 10, 2009, 659-665.

D. Di Pierro, A. Rizzello, G. Cicoria, **F. Lodi**, M. Marengo, D. Pancaldi, S. Trespidi, S.

Boschi. Radiolabelling, quality control and radiochemical purity assessment of the Octreotide analogue ^{68}Ga DOTA NOC. *Appl. Rad. Isot.* 66 (2008), 1091-1096.

Mario Marengo, **Filippo Lodi**, Silvia Magi, Gianfranco Cicoria, Davide Pancaldi, Stefano Boschi. Assessment of radionuclidic impurities in 2-[^{18}F]Fluoro-2-deoxy-D-glucose ([^{18}F]FDG) routine production. *Appl. Rad. Isot.* 66 (2008), 295-302.

Filippo Lodi, Silvia Trespidi, Donato Di Pierro, Mario Marengo, Mohsen Farsad, Stefano Fanti, Roberto Franchi and Stefano Boschi. A simple tracerlab module modification for automated on-column [^{11}C]methylation and [^{11}C]carboxylation. *Appl. Rad. Isot.* 65 (2007), 691-695.

Publications

SCIENTIFIC BOOK CHAPTERS AND BOOK REVIEWS

Elia Anna Turolla, **Filippo Lodi**, Gianfranco Cicoria: Tecniche analitiche di controllo di qualità. *Compendio di Radiochimica e Radiofarmacia*, Minerva Medica 2020

Stefano Boschi, **Filippo Lodi**: Radiofarmaci marcati con Gallio-68. *Compendio di Radiochimica e Radiofarmacia*, Minerva Medica 2020

Filippo Lodi, Claudio Malizia, Stefano Costa: Application of Radiopharmacy in Oncology. *Radiopharmaceuticals, application, insights and future*, Lambert Academic Publishing 2016

Filippo Lodi and Stefano Boschi: Quality Control of PET Radiopharmaceuticals. *Basic Science of PET Imaging*, Springer 2016

Stefano Boschi and **Filippo Lodi**: Chemistry of PET Radiopharmaceuticals: Labelling Strategies. *Basic Science of PET Imaging*, Springer 2016

Boschi S, Malizia C, **Lodi F**. Overview and perspectives on automation strategies in (^{68}Ga) radiopharmaceutical preparations. *Theranostics, Gallium-68, and Other Radionuclides*. Springer 2012

Filippo Lodi and Stefano Boschi. Clyde N. Cole, Stanley M. Shaw and Richard J. Kowalsky (Eds): *Nuclear Pharmacy Quick Reference*, American Pharmacists Association, Washington, DC, 2012. ISBN: 978-1-58212-151-2. Eur. J. Nucl. Med. Mol. Im. 2012, Volume 39, Number 8, Pages 1363-1364.

Filippo Lodi, Assunta Carpinelli, Claudio Malizia and Stefano Boschi. Chapter 19: Synthesis of [^{11}C]-Meta-hydroxyephedrine ([^{11}C]MHED). *Radiochemical Syntheses, Radiopharmaceuticals for Positron Emission Tomography: Volume 1* (Wiley Series on Radiochemical Syntheses Peter J. H. Scott, Brian G. Hockley 2012).

Filippo Lodi, Claudio Malizia and Stefano Boschi. Chapter 29: Synthesis of [^{11}C]Acetate. *Radiochemical Syntheses, Radiopharmaceuticals for Positron Emission Tomography: Volume 1* (Wiley Series on Radiochemical Syntheses Peter J. H. Scott, Brian G. Hockley 2012).

Projects

IAEA RESEARCH COORDINATION PROJECTS

Stefano Boschi, Filippo Lodi

"Development of Ga-68 based PET-Radiopharmaceuticals for Management of Cancer and other Chronic Diseases"

Gianfranco Cicoria, Filippo Lodi, Claudio Malizia, Mario Marengo, Stefano Boschi

"Process development for routine production of ^{64}Cu : Part 1 Electroplating, targetry and automation"

Gianfranco Cicoria, Filippo Lodi, Claudio Malizia, Mario Marengo, Stefano Boschi

“Preliminary Results on production and quality control of ^{64}Cu -ATSM”

Gianfranco Cicoria, Davide Pancaldi, Filippo Lodi, Claudio Malizia, Stefano Costa, Mario Marengo, Stefano Boschi

“Production of ^{64}Cu and synthesis of ^{64}Cu -ATSM”